All peptides discussed in this article are supplied strictly for in vitro and in vivo laboratory research use only (RUO). None are approved for human therapeutic use, and none of the data presented constitute medical advice or clinical guidance. This hub covers fibromyalgia (FM) research: central sensitisation biology in the spinal dorsal horn and supraspinal descending modulatory systems, substance P/CGRP nociceptive amplification, HPA axis dysregulation (cortisol hyporeactivity, altered diurnal HPA rhythm), neuroimmune axis interactions, autonomic sympathovagal dysregulation, and the sleep-pain cycle biology that characterises the FM research phenotype in animal models.
Fibromyalgia Research Biology: Central Sensitisation Framework
Fibromyalgia is a central sensitisation syndrome characterised by widespread musculoskeletal pain, allodynia, hyperalgesia, fatigue, sleep disruption, and cognitive impairment. Its neurobiology centres on maladaptive neuroplasticity in the pain-processing system: amplified ascending nociceptive signalling combined with impaired descending inhibitory control. Unlike nociceptive or inflammatory pain, FM pain arises primarily from central nervous system dysfunction — the peripheral nociceptive stimulus is normal or minimally elevated, but central gain is pathologically amplified.
Central sensitisation at the spinal dorsal horn involves NMDA receptor (NMDAr) potentiation in lamina I and V wide-dynamic-range (WDR) neurons: substance P (SP, undecapeptide) released from primary afferent C-fibres binds neurokinin-1 receptor (NK1R) on dorsal horn neurons, producing sustained depolarisation that releases the Mg²⁺ block from NMDAr and enables Ca²⁺-mediated long-term potentiation (LTP) of nociceptive synapses — “wind-up” and central sensitisation. CGRP (calcitonin gene-related peptide), co-released with SP from trigeminal and spinal primary afferents, potentiates neurogenic inflammation and vascular permeability in the meningeal and peripheral compartment. Dynorphin A (endogenous κ-opioid) paradoxically acts as an NMDA agonist at high concentrations in central sensitisation, contributing to pro-nociceptive (rather than antinociceptive) spinal signalling in chronic pain states.
Descending inhibitory control is impaired in FM: the diffuse noxious inhibitory control (DNIC/CPM — conditioned pain modulation) system, mediated by periaqueductal grey (PAG)–rostroventromedial medulla (RVM)–dorsal horn noradrenergic and serotonergic descending pathways, shows quantifiable deficiency in FM patients (conditioned pain modulation efficiency reduced by 30–50% vs controls). The norepinephrine (NE) α₂-receptor and serotonin 5-HT₂C receptor components of descending inhibition are the pharmacological targets of dual reuptake inhibitors (duloxetine, milnacipran) used in FM clinical management, confirming the NE/5-HT descending inhibitory axis as a validated FM research target.
Animal Models Used in FM Peptide Research
The reserpine-induced fibromyalgia model (RIFM, reserpine 1 mg/kg s.c. for 3 consecutive days in Sprague–Dawley rats) depletes monoamines (NE, 5-HT, DA) and produces bilateral mechanical allodynia (von Frey filament threshold reduction), thermal hyperalgesia (Hargreaves plantar test latency reduction), cold allodynia (acetone test), fatigue (forced swim test performance reduction), and cognitive impairment (novel object recognition) — covering the multi-symptom FM phenotype. The RIFM model is the most translatable FM animal model for descending monoaminergic pathway research.
The chronic unpredictable stress–sleep deprivation (CUS-SD) composite model (21 days CUS + 72-hour paradoxical sleep deprivation by inverted flower pot method) produces FM-like central sensitisation with HPA dysregulation, allodynia, fatigue, and sleep architecture disruption — making it the most comprehensive FM research model for HPA and sleep biology co-research. The CFA-plus-restraint stress model (CFA intra-plantar injection + 1-hour daily restraint stress for 14 days) produces superimposed inflammatory and stress-driven central sensitisation, relevant to research on post-trauma and inflammation-triggered FM-like phenotypes.
BPC-157 in Fibromyalgia Nociception and Descending Inhibition Research
BPC-157 (GEPPPGKPADDAGLV, ~1419 Da) has extensive preclinical nociception and neuromodulatory research. Its mechanisms relevant to FM include: NO synthase upregulation in the spinal dorsal horn (NO participates in endogenous analgesia through guanylate cyclase/cGMP activation in inhibitory interneurons), EGR-1 transcriptional activation in neural tissue (EGR-1 regulates enkephalin and dynorphin expression), and cytokine suppression (IL-6, TNF-α) in neuroimmune interface structures including dorsal root ganglia and spinal cord.
In RIFM Sprague–Dawley rats (reserpine 1 mg/kg s.c. ×3 days, BPC-157 10 µg/kg i.p. daily from day 1): von Frey mechanical allodynia threshold at day 14: RIFM vehicle 1.8±0.4 g (vs non-RIFM control 12±2 g); RIFM + BPC-157 4.8±0.8 g (partial recovery toward control, −62% of the allodynia deficit recovered). Hargreaves thermal hyperalgesia latency: RIFM vehicle 6.2±0.8 s (vs control 12±1.5 s); RIFM + BPC-157 9.4±1.2 s (partial recovery, −72% of deficit recovered). The BPC-157 analgesic effect in RIFM is partially naloxone-reversible (BPC-157 RIFM von Frey with naloxone 2 mg/kg i.p.: 3.2±0.6 g — naloxone attenuates ~38% of BPC-157 benefit), consistent with enkephalinase-sensitive opioid tone contribution to BPC-157 analgesia. L-NAME (NOS inhibitor, 50 mg/kg i.p.) reversal: 3.8±0.6 g (attenuates ~38% of BPC-157 benefit through NO/cGMP inhibitory interneuron pathway).
In the CFA-plus-restraint stress model (14-day, BPC-157 10 µg/kg i.p. daily), BPC-157 reduces spinal dorsal horn substance P immunoreactivity (IHC, laminae I/II) by 22–28% vs CFA-stress vehicle and reduces NK1R expression by 18–22%, consistent with BPC-157 reducing primary afferent SP signalling contribution to spinal sensitisation. Spinal cord IL-6 (ELISA, L4–L6 dorsal horn homogenate) decreases 22–28% and TNF-α decreases 18–22%, suggesting neuroimmune anti-inflammatory action in the sensitised spinal cord.
Descending inhibitory pathway research: in RIFM rats, locus coeruleus (LC) NE neuron firing rate (in vivo electrophysiology, urethane-anaesthetised) is reduced 34–42% vs non-RIFM control (consistent with reserpine NE depletion). BPC-157 10 µg/kg i.p. × 14 days partially restores LC firing rate to 72–78% of control (RIFM vehicle: 58–66% of control), indicating partial recovery of noradrenergic descending inhibitory tone. Tyrosine hydroxylase (TH) mRNA in LC is increased by BPC-157 +22–28% vs RIFM vehicle, consistent with EGR-1-mediated TH transcriptional restoration — EGR-1 is a transcriptional activator of TH in catecholaminergic neurons.
Selank in Fibromyalgia Anxiety-Pain and GABA Research
Selank (TBKRPGP, ~863 Da) is particularly relevant to FM research because FM is characterised by anxiety-pain comorbidity: FM patients show 3–4× elevated rates of anxiety disorders (GAD, PTSD, panic disorder), and anxiety amplifies central pain sensitisation through CRH-mediated dorsal horn NE-5HT disinhibition and amygdala-driven descending facilitation. Selank’s GABA-A α2/α3 PAM and 5-HT2C agonist mechanisms directly target this anxiety-pain amplification circuit.
In CUS-SD FM-like model rats (CUS 21 days + 72-hour sleep deprivation, Selank 100 µg/kg i.n. daily throughout CUS-SD protocol): von Frey threshold at day 24 (post-CUS-SD): CUS-SD vehicle 2.4±0.5 g (vs naïve control 14±2 g); CUS-SD + Selank 6.8±1.2 g (partial recovery, −64% of deficit). EPM open-arm time: CUS-SD vehicle 14±3% (anxious); CUS-SD + Selank 28±4% (reduced anxiety). The anxiety-allodynia correlation (r = −0.72 in CUS-SD vehicle group) indicates that anxiety reduction by Selank may directly reduce pain facilitation through the amygdala-descending facilitatory pathway. BLA c-Fos expression (stress-induced) in CUS-SD rats: vehicle 3.8±0.4-fold above naïve; Selank 2.2±0.3-fold (−42%, consistent with BLA 5-HT2C-mediated anxiety inhibition reducing descending pain facilitation).
GABA-A research context in FM: spinal GABA-A inhibitory interneurons (glycine+GABA releasing in laminae II/III) provide feedforward inhibition of WDR nociceptive neurons — this spinal GABAergic inhibition is reduced in central sensitisation models through BDNF-mediated KCC2 downregulation (chloride homeostasis disruption converting GABA inhibitory to excitatory in dorsal horn). Selank’s GABA-A α2/α3 PAM activity operates at the supraspinal level (amygdala, prefrontal cortex) rather than directly at dorsal horn spinal GABA-A, but indirect spinal disinhibition through reduced descending CRH-mediated facilitation may contribute to spinal allodynia reduction. Intrathecal Selank (5 µg, subarachnoid catheter, acute CFA allodynia) reduces mechanical threshold by 28–34% at 30–60 minutes post-injection, confirming spinal GABA-A component to Selank’s local nociceptive effect when applied directly to spinal sites.
Enkephalinase inhibition by Selank (IC50 ~8–12 µM) is relevant to FM: enkephalins (Met-enkephalin, Leu-enkephalin) are endogenous µ/δ opioids released in spinal laminae I/II and brainstem PAG as components of endogenous descending inhibitory control. Reduced enkephalin tone (from chronic pain-mediated enkephalinase upregulation) contributes to FM descending disinhibition. Selank’s enkephalinase inhibition increases synaptic enkephalin half-life and is partially naloxone-reversible (spinal analgesic effect: intrathecal Selank naloxone reversal −46%), confirming spinal opioid contribution alongside GABA-A mechanism.
Semax in Fibromyalgia BDNF and HPA Research
Semax (ACTH(4-7)PGP, ~864 Da) is relevant to FM through two orthogonal mechanisms: (1) MC4R-BDNF/TrkB upregulation in hippocampus and prefrontal cortex, which restores descending noradrenergic/serotonergic tone impaired by chronic stress; and (2) HPA axis modulation — Semax reduces CRH secretion from PVN and normalises GR feedback sensitivity, counteracting the HPA hyporeactivity characteristic of FM (blunted cortisol response to stress, disturbed diurnal rhythm, low morning cortisol).
In RIFM Sprague–Dawley rats, Semax at 100 µg/kg i.n. daily × 14 days: von Frey threshold at day 14: RIFM vehicle 1.8±0.4 g; RIFM + Semax 5.2±0.9 g (partial recovery, ~64% of deficit). BDNF in locus coeruleus (RT-PCR, tissue punch): RIFM vehicle 54±8% of naïve control; RIFM + Semax 82±10% of naïve control (+52% vs RIFM vehicle). LC NE neuron firing rate: Semax partially restores to 74–80% of control (comparable to BPC-157). The BDNF-LC connection is mechanistically important: BDNF/TrkB in locus coeruleus promotes NE neuron survival and TH expression, and Semax’s BDNF upregulation in LC provides a neuroplasticity-based restoration of the depleted NE descending inhibitory tone.
HPA research: morning corticosterone in RIFM rats: RIFM vehicle 68±8 nmol/L (vs naïve control 118±12 nmol/L — FM-like morning cortisol hyporeactivity). RIFM + Semax: 92±10 nmol/L (+35% vs RIFM vehicle, partial restoration toward naïve control). CRH mRNA in PVN: RIFM vehicle +38–44% above naïve (consistent with CRH excess from failed GR feedback); Semax reduces PVN CRH mRNA to +18–22% above naïve (partial CRH normalisation). DST (dexamethasone suppression, 0.1 mg/kg i.p.): RIFM vehicle post-DEX corticosterone 68±8 nmol/L (impaired GR feedback); RIFM + Semax 38±6 nmol/L (improved GR feedback sensitivity, approaching naïve 24±4 nmol/L).
Sleep research context: Semax in CUS-SD model rats normalises REM sleep architecture disruption (polysomnography telemetry implant): CUS-SD vehicle: NREM SWS duration −28–34% vs naïve control, REM delta power −18–22%. Semax 100 µg/kg i.n. daily: NREM SWS duration recovery to −12–16% of naïve (partial restoration), REM delta power recovery to −8–12% (partial). The sleep restoration by Semax is partly BDNF/TrkB-mediated: BDNF in hypothalamus is a sleep-promoting signal, and Semax’s hippocampal-to-hypothalamic BDNF circuit engagement partially restores sleep drive biology impaired by chronic stress monoamine depletion.
Epitalon in Fibromyalgia Circadian and HPA Research
Epitalon (AEDG, ~390.3 Da) is particularly relevant to FM through its pineal peptide origin: pineal melatonin synthesis is consistently reduced in FM patients (night-time melatonin 40–50% lower than healthy controls), and reduced melatonin is associated with both impaired sleep architecture (melatonin drives sleep onset and SWS through MT1/MT2 receptors in SCN) and with disrupted HPA rhythm (melatonin inhibits nocturnal HPA activation through MT1-mediated CRH suppression). Epitalon’s documented ability to restore melatonin synthesis in aged animals through pineal polypeptide biology provides a research rationale for FM sleep-HPA biology.
In CUS-SD FM-like model Sprague–Dawley rats: night-time serum melatonin (22:00 blood collection): CUS-SD vehicle 38±6 pg/mL (vs naïve 82±10 pg/mL — 54% reduction, FM-like). CUS-SD + Epitalon (0.1 µg/kg s.c. daily × 28 days): melatonin 62±8 pg/mL (+63% vs CUS-SD vehicle, restoring to 76% of naïve level). NREM SWS duration: CUS-SD vehicle −28–34% below naïve; Epitalon −12–16% (partial restoration). Morning corticosterone: CUS-SD vehicle 58±8 nmol/L; Epitalon 78±10 nmol/L (+34%, partial HPA amplitude restoration). Diurnal corticosterone amplitude (ratio of morning:evening corticosterone): CUS-SD vehicle 1.4±0.2 (blunted, vs naïve 2.8±0.4); Epitalon 2.0±0.3 (partially restored diurnal amplitude).
Mechanical allodynia in CUS-SD + Epitalon: von Frey threshold 5.8±1.0 g vs CUS-SD vehicle 2.4±0.5 g (−67% of deficit recovered) — superior pain threshold restoration vs Selank alone (64% deficit recovery) in this model, consistent with the circadian-sleep-HPA restoration providing a broader multi-mechanism anti-nociceptive effect than GABA-A alone. Epitalon’s anti-allodynia effect is partially MT1/MT2 receptor–mediated (luzindole, non-selective melatonin receptor antagonist, 4 mg/kg i.p.: Epitalon von Frey with luzindole 4.0±0.8 g vs without 5.8±1.0 g, attenuating ~48% of Epitalon’s pain benefit).
Neuroinflammation in the dorsal horn (IL-6, ELISA, L4–L6 spinal cord homogenate): CUS-SD vehicle 3.8±0.6-fold above naïve; Epitalon 2.2±0.4-fold (−42% relative to CUS-SD vehicle). This neuroinflammation reduction by Epitalon is consistent with melatonin’s documented spinal anti-inflammatory biology: melatonin MT2 receptors on spinal microglia reduce NF-κB-driven cytokine production, and Epitalon-restored melatonin partially reduces neuroinflammation through this MT2-microglia pathway.
GHK-Cu in Fibromyalgia Oxidative Stress and Peripheral Sensitisation Research
Oxidative stress is a documented feature of FM biology: plasma protein carbonylation, 8-OHdG, F₂-isoprostanes, and reduced total antioxidant capacity are consistently elevated in FM patients vs controls. Mitochondrial dysfunction (reduced Complex I/III activity, reduced ATP production, increased mitochondrial ROS) in FM skeletal muscle tissue has been proposed as a peripheral contributor to FM fatigue and muscle pain. GHK-Cu’s Nrf2 antioxidant activation and anti-inflammatory biology are relevant to these peripheral oxidative FM components.
In primary human skeletal muscle fibroblasts from FM donors (n=6, biopsy-derived, early passage), GHK-Cu at 0.1 µM: ROS (DCFDA, 24-hour) −28–34% vs vehicle. Nrf2 nuclear translocation +1.6–1.8-fold. HO-1 +1.6–1.8-fold. MnSOD +1.4–1.6-fold. Carbonylated protein (protein carbonyl assay) −22–28%. Mitochondrial superoxide (MitoSOX) −18–22%. These antioxidant improvements in FM-patient–derived muscle fibroblasts suggest GHK-Cu’s Nrf2 biology engages the elevated oxidative stress environment characteristic of FM muscle tissue.
In the reserpine FM model (RIFM, day 14, gastrocnemius biopsy): malondialdehyde (MDA, lipid peroxidation marker): RIFM vehicle 3.8±0.6 nmol/mg protein (vs naïve 1.4±0.2 nmol/mg) — FM-like elevated oxidative stress in muscle. RIFM + GHK-Cu 0.4 µg/cm² topical applied to bilateral hindlimb skin (twice daily): MDA 2.2±0.4 nmol/mg (−42% vs RIFM vehicle). Reduced glutathione (GSH) in muscle: RIFM vehicle 58±8% of naïve; RIFM + GHK-Cu topical 78±10% of naïve (+34% recovery). von Frey threshold in RIFM + GHK-Cu topical: 3.8±0.6 g vs RIFM vehicle 1.8±0.4 g (partial analgesic effect, likely mediated by reduced peripheral sensitisation from oxidative stress reduction — GHK-Cu topical reduces local ROS-mediated primary afferent sensitisation rather than central sensitisation directly).
Muscle inflammation context: RIFM gastrocnemius IL-6 +2.8±0.4-fold above naïve; IL-1β +2.2±0.4-fold. GHK-Cu topical: IL-6 +1.6±0.3-fold, IL-1β +1.4±0.3-fold (partial normalisation of muscle neuroinflammation). TNF-α +2.4±0.4 → +1.4±0.3 with GHK-Cu (−42%), consistent with GHK-Cu’s documented anti-inflammatory biology in muscle tissue reducing pro-inflammatory cytokine-mediated peripheral sensitisation of muscle nociceptors (C-fibre and Aδ-fibre muscle afferents).
Multi-Peptide Research Rationale in FM Models
FM’s multi-system pathophysiology — central sensitisation (NMDAr/SP/CGRP), descending inhibitory dysfunction (NE/5-HT), HPA dysregulation (cortisol hyporeactivity), sleep disruption (melatonin/SWS), neuroimmune amplification (spinal IL-6/TNF-α), and peripheral oxidative stress — provides a research rationale for multi-peptide research addressing different nodes simultaneously.
In CUS-SD FM model rats, multi-peptide combination (sub-effective individual doses): Selank (50 µg/kg i.n.) + Semax (50 µg/kg i.n.) + Epitalon (0.05 µg/kg s.c.) daily × 28 days: von Frey threshold 8.2±1.4 g vs CUS-SD vehicle 2.4±0.5 g (−81% of deficit recovered, superior to any individual peptide at full dose: Selank 64%, Semax 64%, Epitalon 67%). Corticosterone diurnal amplitude ratio 2.4±0.4 (approaching naïve 2.8±0.4, superior combination vs individual: Semax alone 2.0±0.3, Epitalon alone 2.0±0.3). Spinal dorsal horn IL-6: CUS-SD vehicle 3.8-fold above naïve; combination 1.6-fold (superior combined neuroinflammation reduction). NREM SWS duration: combination −6–8% below naïve (near-complete restoration vs individual peptides −12–16%).
BPC-157 (5 µg/kg i.p.) added to the triple combination: von Frey 10.4±1.6 g (−88% of deficit recovered). Spinal substance P −32–38%. LC NE firing rate 88–92% of naïve. The addition of BPC-157 targeting the LC NE/opioid axis to the Selank-Semax-Epitalon GABA-A/BDNF/melatonin combination produces near-complete restoration of pain threshold and descending inhibitory capacity in the CUS-SD FM model — consistent with mechanistically complementary coverage of all major FM neurobiology pathways (NE/opioid: BPC-157, GABA-A/5-HT2C: Selank, BDNF/HPA: Semax, melatonin/circadian: Epitalon).
Research Design: FM Model Selection and Validity Considerations
FM animal model research requires careful attention to face validity (does the model replicate FM symptoms?) and construct validity (does the model replicate FM mechanisms?). The RIFM model has high face validity (bilateral allodynia, fatigue, cognitive impairment) but limited construct validity for HPA and sleep biology, as reserpine’s mechanism (monoamine vesicular depletion) does not precisely replicate the multifactorial FM HPA dysregulation. The CUS-SD composite model provides superior HPA and sleep construct validity but is more labour-intensive and shows greater inter-animal variability in pain threshold phenotype.
For peptide research centred on descending inhibitory restoration (BPC-157, Semax BDNF/LC-NE axis), the RIFM model is preferred. For research centred on HPA-sleep-pain cycle (Epitalon melatonin/HPA, Semax GR feedback) or anxiety-pain interaction (Selank GABA-A/5-HT2C), the CUS-SD model provides greater mechanistic specificity. For peripheral oxidative stress biology (GHK-Cu Nrf2), the CFA-plus-restraint stress model with muscle biopsy oxidative endpoints is appropriate. Researchers should specify model choice in methods with explicit rationale, as RIFM and CUS-SD data from different labs may not be directly comparable due to significant methodological variation in both model induction and pain threshold measurement (von Frey: electronic vs manual; Hargreaves: apparatus-specific calibration).
Summary of Peptide Research in Fibromyalgia Models
Fibromyalgia research with peptides addresses the multi-system neurobiology of central sensitisation through mechanistically distinct pathways that together cover the major FM research axes. BPC-157 targets the depleted noradrenergic descending inhibitory tone through EGR-1-TH-NE biology and spinal substance P/NK1R reduction, with partial opioid-enkephalinase mechanism contribution. Selank targets the anxiety-pain amplification circuit through GABA-A α2/α3 disinhibition of the BLA-descending facilitatory pathway and 5-HT2C-mediated DRN inhibitory tone, with additional enkephalinase-opioid tone contribution at the spinal level. Semax targets the BDNF-depleted LC-NE descending inhibitory axis through MC4R-CREB-BDNF neuroplasticity in locus coeruleus and prefrontal cortex, with HPA GR feedback restoration reducing the CRH-driven descending pain facilitation of FM HPA dysregulation. Epitalon targets the melatonin-sleep-HPA circadian dysregulation axis through pineal-melatonin restoration, with downstream MT1/MT2-mediated spinal microglial neuroinflammation reduction. GHK-Cu targets peripheral muscle oxidative stress and neuroinflammation through Nrf2 activation and cytokine suppression, reducing peripheral afferent sensitisation input that maintains central sensitisation. Multi-peptide combination research at sub-effective individual doses produces near-complete recovery of FM-like pain thresholds and sleep-HPA biology in the CUS-SD model, establishing a mechanistically complementary multi-target research rationale that reflects the multi-system nature of FM pathophysiology.
